← 홈

흑색종

106개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 106개
AntibodyBHotMerckVedotin ± Pe…Phase 3

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Locally Advanced Esophageal Squamous Cel

#LocallyAdvancedEsophagealSquamou#Antibody#Phase3#인기#항체+5
효능 ORR 41.6%임상시험 155상태 RECRUITING
AntibodyBHotMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3
효능 ORR 56.1%임상시험 110상태 ACTIVE
ADCCBiologicEli Lilly and CompanyPhase 2

Abemaciclib (Abemaciclib)

Advanced Cancer; Metastatic Melanoma · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 32.9%임상시험 77상태 RECRUITING
ADCBiologicMedImmune LLCPhase 2

Dabrafenib (Dabrafenib)

Melanoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 100%임상시험 69상태 DISCONTINUED
CGTBiologicMerck Sharp & Dohme LLCPhase 3

Recombinant Interferon Alfa-2b (Recombinant Interferon Alfa-2b)

Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8 · HER2

#HER2#CGT#Phase3#인기#세포유전치료+5
임상시험 63상태 ACTIVE
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab and nivolumab)

Mesothelioma; Pancreatic Cancer · Uveal Melanoma, Metastatic

#UvealMelanomaMetastatic#Antibody#Phase2#인기#항체+5
효능 ORR 77.8%임상시험 59상태 RECRUITING
CGTBiologicInge Marie SvanePhase 1

Proleukin (Proleukin)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#인기#세포유전치료+5
효능 ORR 33.3%임상시험 59상태 RECRUITING
CGTBiologicMedigen Vaccine Biologics Corp.Phase 1

Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell, Recombinant Oncolytic HSV-2 Therapeutic Injecta, Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF))

Melanoma Stage IV · Melanoma Stage IV

#MelanomaStageIV#CGT#Phase1#인기#세포유전치료+4
임상시험 58상태 ACTIVE
ADCBiologicAmerican Society of Clinical On…Phase 2

Dabrafenib plus Trametinib (Dabrafenib plus Trametinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
CGTBiologicImmunityBio, Inc.Phase 2

ALT-803 (ALT-803)

Melanoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 33%임상시험 56상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 3

nivolumab (Opdivo, Nivolumab/Relatlimab)

Cancer · Melanoma

#Melanoma#Antibody#Phase3#인기#항체+4
효능 ORR 92.9%임상시험 55상태 RECRUITING
AntibodyWei-Che KoPhase 3

Sarilumab (Sarilumab)

Skin Inflammation; Allergic Contact Dermatitis · Melanoma

#Melanoma#Antibody#Phase3#인기#항체+5
효능 ORR 3.5%임상시험 50상태 RECRUITING
CGTBiologicImmunityBio, Inc.Phase 2

haNK (haNK)

Melanoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 5%임상시험 40상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 77.8%임상시험 32상태 RECRUITING
ADCBiologicstaleMerckPhase 2

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

Melanoma · PD-1

#PD-1#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 38%임상시험 31상태 DISCONTINUED
AntibodystaleJunshi BiosciencesPhase 2

humanized anti-PD-1 monoclonal antibody toripalimab (humanized anti-PD-1 monoclonal antibody toripalimab)

Advanced Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 2

Dabrafenib Mesylate (Dabrafenib Mesylate)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 61%임상시험 24상태 RECRUITING
AntibodystaleDiwakar DavarPhase 2

Domvanalimab (Domvanalimab)

Melanoma · Metastatic Urothelial Cancer

#MetastaticUrothelialCancer#Antibody#Phase2#항체#면역항체+3
임상시험 22상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab/Quavonlimab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0.0%임상시험 12상태 ACTIVE
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab Injection [Keytruda])

Gestational Trophoblastic Neoplasia · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+3
임상시험 10상태 ACTIVE

1 / 6 페이지

← 이전다음 →